Summary of evidence of impact of remote patient monitoring tools on patient outcomes across various disease areas
| Disease area | Participants | Intervention | Follow-up | Outcome |
|---|---|---|---|---|
| Cardiology/congestive heart failure29 | 99 patients receiving cardiac resynchronisation therapy | Daily remote monitoring (RM) vs standard programme of in-office visits | 7 months | Rate of detection of clinical adverse events was 23.8% in the RM group vs 48.7%; HR 0.14 (95% CI 0.06 to 0.37) |
| Diabetes30 | 301 patients with type 2 diabetes | Automated telemonitoring, clinician notification and informal caregiver involvement | 3–6 months | Significant improvements over time in long-term medication non-adherence, physical functioning, depressive symptoms and diabetes-related distress (all p<0.001). Significant improvements in patient-reported frequency of weekly medication adherence, self-monitored blood glucose (SMBG) performance, checking feet and abnormal SMBG readings |
| Hypertension31 | 778 patients taking antihypertensive drugs | Usual care vs usual care with home blood pressure monitor (BPM) vs web-based pharmacist care with home BPM | 12 months | 55% of patients in the pharmacist-care group vs 37% in the usual care with home BPM group had BP <140/90 mm Hg. Home BPM accounted for 30.3% of the intervention effect, secure electronic messaging for 96%, and medication intensification for 29.3% |